Benjamin Wolozin on Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17.

COMMENT This represents a novel an potentially important line of research that could be used to help patients with diseases that arise from genetically inherited mutations. 0 bwolozin

John Olney on A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase.

COMMENT Perhaps they are right that this provides a useful model but they have not shown yet how useful it can be. 0 OlneyJ

Paul Coleman on Use of proxies to measure health and functional outcomes in effectiveness research in persons with Alzheimer disease and related disorders.

COMMENT This may contain information useful for retrospective studies of AD. 0 Paul_Coleman

John Olney on A new paradigm for neurotoxicity by FAD mutants of betaAPP: a signaling abnormality.

COMMENT Nishimoto reviews a hypothesis generated by his group pertaining to beta APP as a signaling receptor molecule which is activated by point mutations. They state that the presence of such mutations cause neuronal cells to undergo apoptotic death by a G prot

Hiroshi Mori on Structural analysis of Pick's disease-derived and in vitro-assembled tau filaments.

COMMENT Careful observations like this one provide further perspective on different mechanisms of pathogenesis of various tau filaments. Pick and AD filaments could be good targets to compare. 0 mori

Hiroshi Mori on Assembled tau filaments differ from native paired helical filaments as determined by scanning transmission electron microscopy (STEM).

COMMENT There are little information to clearly show the difference between normally assembled tau and pathologically formed PHF. This is the paper to show such difference morphologically. 0 mori

Paul Coleman on A preliminary study of dietary aluminium intake and risk of Alzheimer's disease.

COMMENT A small study in which the number of variables (foods, medical history items, etc.) appears to significantly exceed the number of cases (23 matched sets). 0 Paul_Coleman

Elliott Mufson on Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau.

COMMENT Noteworthy 0 emufson

Gerry Fischbach on Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro.

COMMENT Interesting link between glucocorticoids (stress) and toxicity due to beta amyloid and glutamate. [However,] The clonal cell line has not proven its value as a model for hippocampal pyramidal cell. 0 gf224

Benjamin Wolozin on Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients.

COMMENT cystatin C is implicated in dementia and this paper provides a mechanism. 0 bwolozin

Hiroshi Mori on Bcl-2 and Bax protein expression in Alzheimer's disease.

COMMENT It is obscure whether apoptosis is involved in AD apthogenesis. Study of bcl-2 and p53 and other related molecules are interesting for understanding neuronal viability in AD brain. 0 mori

Paul Coleman on Posttranslational changes in band 3 in aging and Alzheimer's disease: do anion and glucose transport changes reflect or foreshadow the eventual metabolic abnormalities?

COMMENT Dr. Kay is the world leader in band 3 work, and in this review paper presents preliminary evidence for differences between AD and controls in posttranslational processing of this protein. 0 Paul_Coleman

Hiroshi Mori on Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease.

COMMENT Bleomycin is a chemical of interest in AD and its metabolic enzyme must be something [of significance]. 0 mori

Hiroshi Mori on Mutations in the transmembrane domain of APP altering gamma-secretase specificity.

COMMENT This paper contains important implication and experimental explanation for gammma-secretase which is believed to play a crucial role in Abeta production 0 mori

Nikolaos K. Robakis on Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease.

COMMENT NGF was considered once a promising drug for AD treatment. Unfortunately it seems to have serious side effects (very common with growth factors). Maybe a better administration route will be found with less side effects. 0 nikos.robakis